

CD30 positive cutaneous T-cell lymphoma – brentuximab vedotin – initial authority application

Online PBS Authorities



Requesting PBS Authorities online provides an immediate assessment in real time.

For more information and how to access the **Online PBS Authorities** system, go to servicesaustralia.gov.au/hppbsauthorities

When to use this form

Use this form to apply for **initial** PBS-subsidised brentuximab vedotin for patients with CD30 positive cutaneous T-cell lymphoma.

Important information

Initial applications to start PBS-subsidised treatment can be made in real time using the **Online PBS Authorities** system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Under no circumstances will phone approvals be granted for **initial** authority applications.

The information in this form is correct at the time of publishing and may be subject to change.

Continuing treatment

This form is ONLY for **initial** treatment.

After an authority application for initial treatment has been approved, applications for **continuing** treatment with brentuximab vedotin can be made in real time using the **Online PBS Authorities** system, or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

Section 100 arrangements for brentuximab vedotin

This item is available to a patient who is attending:

- an approved private hospital
- a public participating hospital, **or**
- a public hospital

and is:

- a day admitted patient
- a non-admitted patient, **or**
- a patient on discharge.

This item is not available as a PBS benefit for in-patients of a public hospital.

Treatment specifics

The patient cannot receive more than 4 cycles of treatment under the **initial** treatment phase and 12 cycles of treatment under the **continuing** treatment phase.

Treatment must not exceed a total of 16 cycles in a lifetime.

For more information

Go to servicesaustralia.gov.au/healthprofessionals

CD30 positive cutaneous T-cell lymphoma – brentuximab vedotin – initial authority application

Online PBS Authorities



You do not need to complete this form if you use the **Online PBS Authorities** system.

Go to servicesaustralia.gov.au/hppbsauthorities

Patient's details

1 Medicare card number

Ref no.

or

Department of Veterans' Affairs card number

2 Family name

First given name

3 Date of birth (DD MM YYYY)

Prescriber's details

4 Prescriber number

5 Family name

First given name

6 Business phone number (including area code)

Alternative phone number (including area code)

Conditions and criteria

To qualify for PBS authority approval, the following conditions must be met.

7 Does the patient have pathologically confirmed CD30 positive cutaneous T-cell lymphoma?

No ☐

Yes ☐

8 The patient has a histopathology report from an Approved Pathology Authority to confirm the diagnosis of:

☐ mycosis fungoides

or

☐ Sézary syndrome

or

☐ primary cutaneous anaplastic large cell lymphoma.

9 Provide details of the histopathology report

Date of the histopathology report (DD MM YYYY)

Unique identifying number/code or provider number

10 The patient has a CD30 positivity of at least 3% of malignant cells confirmed by:

☐ a histology report on the tumour sample

or

☐ a flow cytometric analysis of lymphoma cells of the blood

11 Provide the following details of the histology or flow cytometry report

Date of the report (DD MM YYYY)

Unique identifying number/code or provider number

12 Has the patient received prior systemic treatment for this condition?

No ☐

Yes ☐

13 Provide dates of most recent treatment

From (DD MM YYYY)

To (DD MM YYYY)



MCA0PB268 2506

14 Is the patient's condition relapsed or refractory?

No ☐

Yes ☐

15 Is this treatment the sole PBS-subsidised systemic anti-cancer therapy for this condition?

No ☐

Yes ☐

16 Will the treatment exceed 4 cycles under this restriction in a lifetime?

No ☐

Yes ☐

Checklist

17  The relevant attachments need to be provided with this form.

☐ Details of the proposed prescription(s).

Privacy notice

18 Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application.

Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at servicesaustralia.gov.au/privacypolicy

Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at servicesaustralia.gov.au/hpos

19 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction
- the information I have provided in this form is complete and correct.

I understand that:

- giving false or misleading information is a serious offence.

☐ I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

--	--	--	--	--	--	--	--	--	--

Prescriber's signature (**only** required if returning by post)



Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos
or
- by post (signature required) to
Services Australia
Complex Drugs Programs
Reply Paid 9826
HOBART TAS 7001